pharma · Respiratory Syncytial Virus Infections · Asthma
MedImmune
MedImmune is a pharma organization headquartered in EU. Primary therapeutic focus areas include Respiratory Syncytial Virus Infections, Asthma, Influenza, Stage III Non-small Cell Lung Cancer, Chronic Obstructive Pulmona
Gaithersburg, USA HQ
1987 Founded
896 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- Gaithersburg, USA
- Founded
- 1987
- Employees
- 896
- Programs
- 9
- Drugs
- 7
- Patents
- 0
Motavizumab, palivizumab
Phase 2 · mab · Respiratory Syncytial Virus Infections
Motavizumab, palivizumab for Respiratory Syncytial Virus Infections is a Phase 2 program (mab) at MedImmune with 1 ClinicalTrials.gov record(s).
Internal code MI-CP127
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- MedImmune
- Phase
- Phase 2
- Modality
- mab
- Indication
- Respiratory Syncytial Virus Infections
- Status
- completed
- Trials
- 1